ORPHA:254688
Complete hydatidiform mole
Also known as: Complete molar pregnancy
Publications
2,003
Trials
2
Interventional, condition-specific
Researchers
1,017
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A form of hydatiform mole characterized by abnormal hyperplastic trophoblasts and hydropic villi due to fertilization of an enucleated ovocyte by one or two haploid spermatozoa that can manifest with vaginal bleeding accompanied by nausea and frequent vomiting, hyperemesis gravidarum, risk of spontaneous miscarriage, hyperthyroidism, and has the potential of developing into choriocarcinoma.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016785
- UMLS:C0678213
- NCIT:C4871
Additional Mondo synonyms (4)
classical hydatidiform Mole · complete Mole · complete hydatid Mole · complete molar pregnancy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,003 matched papers (875 in last 10 years) Source
- Phenotype characterisedPresent
2 HPO annotations (e.g. Hydatidiform mole) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
2
Associated phenotypes · MONDO:0016785
- Hydatidiform mole
Showing 1 of 2 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,003
2,003 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,003 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
875 in the last 10 years · low confidence
Phrase hits: 2,003 · MeSH hits: 0
Who's working on it?
1,017
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Braga A9 papers · 2026
Faculty of Medicine, Postgraduate Program in Medical Sciences, Fluminense Federal University, Rua Ataíde Parreiras, 100, Bairro de Fátima, Niterói, RJ 24070-090, Brazil; Department of Obstetrics and Gynecology, Rio de Janeiro Trophoblastic Disease Center, Maternity School of Rio de Janeiro Federal University, Rua Laranjeiras, 180, Laranjeiras, Rio de Janeiro, RJ 22240-003, Brazil; Postgraduate Program in Applied Health Sciences, Vassouras University, Av. Expedicionário Osvaldo de Almeida Ramos, 250, Bloco 03, 2 andar, Centro, Vassouras, RJ 27700-000, Brazil. Electronic address: antonio.braga@ufrj.br.
Papers in Europe PMC - 02Sun SY6 papers · 2026
Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), Sao Paulo 04023-062, SP, Brazil.
Papers in Europe PMC - 03Bolze PA5 papers · 2026
Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
Papers in Europe PMC - 04Cai L5 papers · 2026
Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR China.
Papers in Europe PMC - 05Kajiyama H5 papers · 2025
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
Papers in Europe PMC - 06Niimi K5 papers · 2025
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. kaorun@med.nagoya-u.ac.jp.
Papers in Europe PMC - 07Nishiko Y5 papers · 2025
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
Papers in Europe PMC - 08Nishino K5 papers · 2025
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
Papers in Europe PMC - 09Qian J5 papers · 2026
Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR China. Electronic address: qianjianhua@zju.edu.cn.
Papers in Europe PMC - 10Wang X5 papers · 2026
Department of Pathology, Liaocheng People's Hospital, Liaocheng, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 6 trials are registered for hydatidiform mole, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
low confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: hydatidiform mole
6
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03785574·RECRUITING·Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
Not reviewed·Conditions: Hydatidiform Mole · Gestational Trophoblastic Neoplasia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 12 · after dedupe 12 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 12 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (12)
- isrctn·ISRCTN17424858·No longer recruiting·Evaluating the CORE-10 as an assessment measure of psychological distress in women 3 months after miscarriage
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86152317·Recruiting·A study to assess the feasibility of treating patients with gestational trophoblastic neoplasia with pre-surgical pembrolizumab prior to their second evacuation and determine if this is a desirable alternative
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35903062·No longer recruiting·Remimazolam vs midazolam cognitive and motor recovery after intravenous conscious sedation for dental extractions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18396096·No longer recruiting·Investigating the microorganisms found in the mouths of healthy people
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13520922·No longer recruiting·Platelet rich fibrin in periodontal surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74959523·No longer recruiting·Short versus long chemotherapy regiment for trophoblastic tumor
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14290358·No longer recruiting·Assessment of the procedure duration and success of alternative emergency treatments for patients with painful dental pulp disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78513432·No longer recruiting·Grant Dental Technology’s Proximerge™ Implant System post-market clinical study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49711898·No longer recruiting·Medical abortion at 10-20 weeks
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63711065·No longer recruiting·Phase II/III Oxabact™ Study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97410750·No longer recruiting·Comparing efficacy of vaginal misoprostol administered at 6-8 hours with 24 hours administration after 200 mg of oral mifepristone for early medical abortions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35300716·No longer recruiting·A comparative pharmacokinetic study of oral mifepristone and vaginal misoprostol in pregnant women
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Complete hydatidiform mole — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Complete hydatidiform mole" OR "Complete molar pregnancy" OR "classical hydatidiform Mole" OR "complete Mole" OR "complete hydatid Mole"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Complete hydatidiform mole" OR "Complete molar pregnancy" OR "classical hydatidiform Mole" OR "complete Mole" OR "complete hydatid Mole"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hydatidiform mole"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (2003) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T11:05:41.194Z
